Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katherine Vandris

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Blood|April 27, 2011
Recombinant interferon-α may retard progression of early primary myelofibrosis: a preliminary reportRichard T Silver, Katherine Vandris, Joshua J Goldman
Leukemia Research|July 24, 2010
JAK2(V617F) allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapyRichard T Silver, Katherine Vandris, Y Lynn Wang, et al.
Leukemia Research|October 11, 2011
Treatment of polycythemia vera with imatinib mesylateRichard T Silver, Michael H Bourla, Katherine Vandris, et al.
Haematologica|November 22, 2011
Decrease in JAK2 V617F allele burden is not a prerequisite to clinical response in patients with polycythemia veraEmil Kuriakose, Katherine Vandris, Y Lynn Wang, et al.
Breast Cancer Research and Treatment|September 21, 2010
A 10-year follow-up of treatment outcomes in patients with early stage breast cancer and clinically negative axillary nodes treated with tangential breast irradiation following sentinel lymph node dissection or axillary clearanceA Gabriella Wernicke, Robert L Goodman, Bruce C Turner, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Blood|April 27, 2011
Recombinant interferon-α may retard progression of early primary myelofibrosis: a preliminary reportRichard T Silver, Katherine Vandris, Joshua J Goldman
Leukemia Research|July 24, 2010
JAK2(V617F) allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapyRichard T Silver, Katherine Vandris, Y Lynn Wang, et al.
Leukemia Research|October 11, 2011
Treatment of polycythemia vera with imatinib mesylateRichard T Silver, Michael H Bourla, Katherine Vandris, et al.
Haematologica|November 22, 2011
Decrease in JAK2 V617F allele burden is not a prerequisite to clinical response in patients with polycythemia veraEmil Kuriakose, Katherine Vandris, Y Lynn Wang, et al.
Breast Cancer Research and Treatment|September 21, 2010
A 10-year follow-up of treatment outcomes in patients with early stage breast cancer and clinically negative axillary nodes treated with tangential breast irradiation following sentinel lymph node dissection or axillary clearanceA Gabriella Wernicke, Robert L Goodman, Bruce C Turner, et al.
Pageof 1